CAP

Identity and Access Management Security Provider BIO-key’s 2021 Revenue Rose 80% to $5.1M, Driven by Demand for Identity-as-a Service Cloud Solutions; Investor Call Today at 10am ET

Retrieved on: 
Tuesday, March 29, 2022
As a service, Expansion, Research, Risk, White, NIMC, Workforce, White House, Element, Federation, International, Nasdaq, GLOBE, Solution, SSO, Commerce, Annual report, Education, Engineering, History, Security (finance), MFA, Health, Industry, Single, Intelisys, Technology, United States Department of Justice, Next, NIST, Investment, IAM, Growth, Coronavirus, Program, Access management, FIDO2, NGEN, Net, COVID, Single sign-on, Partnership, Identity management, Organization, Contract, The Act, Private Securities Litigation Reform Act, Justice, Calendar, Patent, CAP, COVID-19, IBB, EMEA, Acquisition, Mobile phone, Cryptocurrency, Online shopping, Risk management, Video game, Pharmaceutical industry, Silviculture, WALL

Awarded U.S. Patent for Enabling Next-generation Continuous Biometric User Authentication , increasing BIO-keys IP Portfolio to 18 patents.

Key Points: 
  • Awarded U.S. Patent for Enabling Next-generation Continuous Biometric User Authentication , increasing BIO-keys IP Portfolio to 18 patents.
  • Swivel Secure generated approximately $3.1M in revenue and $578K in operating income in calendar 2021.
  • Currently, IDaaS revenue accounts for approximately 80% of our total software and non-recurring service revenue.
  • Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made.

AnPac Bio-Medical Sciences Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing

Retrieved on: 
Saturday, March 26, 2022
Hearing, Company, Risk, CLIA, CDA, Form, Letter, Compliance, Staff, Panel, Listing Rules, Failure, CEO, U.S. Securities and Exchange Commission, American, Security (finance), Frost & Sullivan, American depositary receipt, Calendar, CAP, Time, GLOBE, Frost, File, Nasdaq

The Company may also apply to list its securities on The Nasdaq Capital Market if it satisfies the requirements for continued listing on that market.

Key Points: 
  • The Company may also apply to list its securities on The Nasdaq Capital Market if it satisfies the requirements for continued listing on that market.
  • The Company is applying to transfer to The Nasdaq Capital Market and will appeal the Letter to seek additional time to meet the requirements to transfer.
  • The Company was provided 180 calendar days, or until March 23, 2022, to regain compliance with the MVLS requirement.
  • The Company intends to request a hearing before a Hearings Panel (the Panel).

Gravity Diagnostics Appoints New President

Retrieved on: 
Tuesday, March 22, 2022
Health, GLOBE, Physician, CEO, CFO, Remington, Technology, Toxicology, Pharmacogenomics, Fortune 500, CAP, Patient, University, Gravity, COVID-19, Pharmaceutical industry, Management

Covington, KY, March 22, 2022 (GLOBE NEWSWIRE) -- Gravity Diagnostics, a CLIA-certified and CAP-accredited laboratory, has announced the promotion of Henry Agent to serve as the companys President.

Key Points: 
  • Covington, KY, March 22, 2022 (GLOBE NEWSWIRE) -- Gravity Diagnostics, a CLIA-certified and CAP-accredited laboratory, has announced the promotion of Henry Agent to serve as the companys President.
  • Currently the companys Chief Financial Officer, Henry will still hold that position while also leading the core diagnostics business for the company.
  • Henry is a seasoned and talented finance executive with years of experience working with companies in stages ranging from start-up to exit, said Tony Remington, CEO and co-founder of Gravity Diagnostics.
  • Gravity Diagnostics is a state-of-the-art CAP-accredited and CLIA-certified laboratory licensed in all 50 states providing innovative laboratory testing in the areas of COVID-19, upper respiratory, toxicology, pharmacogenetics, sexually transmitted infections, and blood hematology.

Sigyn Therapeutics Announces Filing of 2021 Annual Report on Form 10-K

Retrieved on: 
Tuesday, March 22, 2022
Company, Therapy, Ammonia, Cytokine, OTC Markets Group, Form 10-K, Liver failure, Investor, Community-acquired pneumonia, Death, Annual report, Hepatic encephalopathy, SEC, Risk, Head, CEO, Severe acute respiratory syndrome coronavirus 2, Food, U.S. Securities and Exchange Commission, Security (finance), MD, Seminal vesicles, Technology, Sepsis, Securities Exchange Act of 1934, CAP, Inflammation, Securities Act of 1933, Investigational device exemption, FASN, COVID-19, MBA, Regulation of tobacco by the U.S. Food and Drug Administration, CPA, University, Septic shock, Infection, Pharmaceutical industry, Medical device, Vaccine, Animal, Operation

via NewMediaWire --Sigyn Therapeutics, Inc. (OTC Markets: “SIGY”) (“Sigyn Therapeutics” or the “Company”), a medical technology company focused on the treatment of pathogen-associated conditions that induce sepsis and other life-threatening disorders, announced today that it has filed its annual report on Form 10-K for the year ended December 31, 2021 with the Securities and Exchange Commission ("SEC") and provided a corporate update. The Company’s Sigyn Therapy™ is a novel blood purification technology designed to perform functions that are beyond the reach of drugs and overcome the limitations of current devices to treat life-threatening inflammatory disorders, including sepsis, the leading cause of hospital deaths worldwide. 

Key Points: 
  • 2021 was a transformative year, during which we advanced Sigyn Therapy from conceptual design to clinical application and added key members to our clinical and management team, stated Jim Joyce, co-founder and CEO of Sigyn Therapeutics.
  • In April 2021, disclosed initial in vitro study observations that demonstrated the ability of Sigyn Therapy to adsorb viral pathogens, including SARS-CoV-2 (COVID-19).
  • A copy of Sigyn Therapeutics annual report is available on the SEC's website at www.sec.gov , and on the Company's website at www.sigyntherapeutics.com under "Financial Info" in the Investors section.
  • This information in this press release contains forward-looking statements of Sigyn Therapeutics, Inc. (Sigyn) that involve substantial risks and uncertainties.

CAP Calls on Congress to Act on Social Determinants of Health During National Minority Health Month

Retrieved on: 
Thursday, March 31, 2022
Public Policy, Government, Pharmaceutical, Managed Care, Health, Healthcare Reform, Consumer, Other Consumer, Congressional News, Views, Health equity, Racism, Congress, Vaccination, College, Legislation, Vaccine, Color, Pathology, 2009 Davis Cup, Medicaid, Health, Marie Cassidy, CAP, Act, COVID-19, Social determinants of health, Physician, Awareness, Annual report, Black, Patient, Health insurance, MD

For National Minority Health Month this April, the College of American Pathologists (CAP) calls for Congress to act on legislation that addresses the social determinants of health in the United States.

Key Points: 
  • For National Minority Health Month this April, the College of American Pathologists (CAP) calls for Congress to act on legislation that addresses the social determinants of health in the United States.
  • National Minority Health Month highlights the importance of improving health and reducing health disparities in the United States, said CAP President Emily Volk, MD, FCAP.
  • Unfortunately, various social determinants contribute to people not getting the recommended health care services they need.
  • The 2022 National Minority Health Month theme is Give Your Community a Boost , which focuses on the importance of COVID-19 vaccination.

Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2021 Financial Results

Retrieved on: 
Monday, March 28, 2022
Health, Fitness & Nutrition, Other Science, General Health, Research, Science, EBITDA, Company, Laboratory, CLIA, Mission statement, Sale, Laboratory developed test, Power purchase agreement, CAC, Gastroenterology, Clinical trial, Growth, CF, GAAP, Bill, SEC, Program, Research, Webcast, Conference, LDT, PIN, LLC, Calendar, LCD, CAP, Facility, Depreciation, CA, Nasdaq, Tax, Traction, Medicare, VP, Partnership, Video game, Pharmaceutical industry, Health insurance, Financial adviser, Cryptocurrency, Security (finance), Bank, Lucid, Share (finance), Cantor, ESOGUARD AND ESOCHECK, LUCID DIAGNOSTICS

A conference call and webcast for todays business update and fourth quarter and year ended December 31, 2021, financial results will take place at 4:30 PM EDT.

Key Points: 
  • A conference call and webcast for todays business update and fourth quarter and year ended December 31, 2021, financial results will take place at 4:30 PM EDT.
  • To access the conference call, listeners should dial 877-407-0789 toll-free in the U.S. or 201-689-8562 and ask to join the Lucid Diagnostics Business Update Conference Call.
  • Lucid processed 303 commercial EsoGuard tests in the fourth quarter of 2021, which represents an approximately 50% increase sequentially from the third quarter and a nearly 200% increase annually from the fourth quarter of 2020.
  • To supplement our unaudited financial results presented in accordance with U.S. generally accepted accounting principles (GAAP), management provides certain non-GAAP financial measures of the Companys financial results.

NAPA Transportation selects SmartDrive SmartSense™ to improve driver and fleet safety

Retrieved on: 
Tuesday, March 29, 2022
SmartDrive, Behavior, LoJack, Fatality, Transport, Multimedia, Compliance, Distracted driving, Eyelid, Intelligence, Workforce, LLC, Travel, Safety, Industry, CAP, CDS, Workflow, Inattentional blindness, Efficiency, History, NAPA, Taxicab, Solera

WESTLAKE, Texas, March 29, 2022 /PRNewswire/ -- Omnitracs, LLC, a Solera company, today announced that NAPA Transportation, Inc., a family-owned carrier of dry van and refrigerated truckloads, has selected its video safety solution, SmartDrive SmartSense™ for Inattentive Driving+, for supporting its driver and fleet safety. 

Key Points: 
  • Omnitracs announced NAPA Transportation has selected its video safety solution for supporting driver and fleet safety.
  • SmartSense for Inattentive Driving+ uses next-generation, computer-vision-based algorithms, and a purpose-built sensor, to help ensure the safety of the fleet.
  • "Solera is excited to be partnering with NAPA Transportation in supporting their driver and fleet safety needs with a common goal of saving lives.
  • Added Joseph Salisbury, CDS, Safety Director, NAPA, "Our goal at NAPA Transportation is to integrate and maintain a best-in-class safety culture, one where every action, activity and decision begins and ends with safety at its core.

GENXYS ADVANCES EFFORT TO REDUCE ADVERSE DRUG REACTIONS, THE FOURTH LEADING CAUSE OF DEATH IN NORTH AMERICA

Retrieved on: 
Thursday, March 24, 2022
Approximation error, Pharmacy, CLIA, Population, Drug, Death, AHRQ, ADR, Precision medicine, Medicine, CEO, Population health, Software, Health, Safety, CAP, Society, Allergy, Awareness, COVID-19, Patient safety, Agency, COVID, Pharmacogenomics, Disulfiram-like drug, Insurance, Pharmaceutical industry, BC

VANCOUVER, BC, March 24, 2022 /PRNewswire/ -- GenXys Health Care Systems, Inc., the global leader in precision prescribing software and embedded pharmacogenetic data, today joins the American Society of Pharmacovigilance in raising awareness of adverse drug reactions (ADRs) on National Adverse Drug Event Awareness Day. With ADRs being the fourth leading cause of death in North America (excluding COVID-19), GenXys is working to reduce ADRs by advancing precision medicine, improving patient safety and treatment response, and reducing health care costs.

Key Points: 
  • With ADRs being the fourth leading cause of death in North America (excluding COVID-19), GenXys is working to reduce ADRs by advancing precision medicine, improving patient safety and treatment response, and reducing health care costs.
  • There are 46 million ADRs leading to 1.3 million emergency room visits each year in the United States alone.
  • According to the Agency for Healthcare Quality and Research (AHRQ), adverse drug events are the costliest and most preventable hospital-acquired condition.
  • GenXys' clinical decision support software, which interprets data from pharmacogenetic testing, is used by major insurance providers, health systems, and pharmacies across North America.

SomaLogic to provide 210 million protein measurements to EPIC researchers to better understand and predict cancer development

Retrieved on: 
Monday, March 21, 2022
Virology, University, Behavior, Principal, CLIA, Conditional sentence, NASDAQ, College, Degenerative disease, Rankings of universities in the United Kingdom, Times Higher Education, Osteoporosis, Neurodegeneration, Genetics, Area studies, Clinical Laboratory, Proteomics, Diet, Survival, Research, School, Africa/Harvard School of Public Health Partnership for Cohort Research and Training, Environment, SomaLogic, World, Incidence, Medicine, Health, Food, Public health, EPIC, Center, Industry, Time, Protein, Twitter, CAP, Nasdaq, Platform, COVID-19, GLOBE, Student, European Prospective Investigation into Cancer and Nutrition, Science, Imperial College London, Reuters, Imperial, Engineering, Pharmaceutical industry, Medical imaging, Dietary supplement, European, Cancer

SomaLogic will use its industry leading SomaScan Assay to analyze 210 million protein measurements from 30,000 samples spanning 15 years of clinical interactions to help researchers understand and predict cancer development.

Key Points: 
  • SomaLogic will use its industry leading SomaScan Assay to analyze 210 million protein measurements from 30,000 samples spanning 15 years of clinical interactions to help researchers understand and predict cancer development.
  • The collaboration between SomaLogic and EPIC aims to develop potentially predictive protein markers in cancer and other diseases.
  • This may lead to fundamental discoveries enhancing clinical understanding of cancer and its treatment, or to the development of screening and diagnostic tools to improve outcomes.
  • Over the EPIC study period of 1992 to 2015, more than 67,000 participants were diagnosed with cancer.

3billion to reveal its diagnostic performance at ACMG annual meeting 2022

Retrieved on: 
Monday, March 21, 2022
Diagnosis, College, EVIDENCE, Public health, Multimedia, Genetics, Research, Disability in Canada, Genomics, Medicine, Lists of diseases, Technology, Knowledge, CAP, Whole genome sequencing, Physician, Accreditation, Patient, ACMG, Pharmaceutical industry, Medical device, Vaccine, Molecular medicine

SEOUL, South Korea, March 21, 2022 /PRNewswire/ -- 3billion announced that Chief Medical Officer Dr. Go Hun Seo will introduce a research poster at ACMG annual meeting 2022, held in Nashville, TN, from March 22 through 26.

Key Points: 
  • SEOUL, South Korea, March 21, 2022 /PRNewswire/ -- 3billion announced that Chief Medical Officer Dr. Go Hun Seo will introduce a research poster at ACMG annual meeting 2022, held in Nashville, TN, from March 22 through 26.
  • After the initial study, 3billion implemented a daily reanalysis pipeline, which resulted in additional 31 patients receiving a diagnosis.
  • For further details, Visit 3billion's Annual Clinical Genetic Meeting 2022 Page.
  • 3billion obtained CAP accreditation from the College of American Pathologists (CAP) in November last year, taking one step closer to the global diagnostic market.